Patents by Inventor Martin L. Moore
Martin L. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230302115Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: ApplicationFiled: October 14, 2022Publication date: September 28, 2023Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
-
Publication number: 20230293660Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.Type: ApplicationFiled: January 14, 2022Publication date: September 21, 2023Inventors: Martin L. Moore, Christina Rostad
-
Patent number: 11471524Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: GrantFiled: September 18, 2020Date of Patent: October 18, 2022Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
-
Publication number: 20220125909Abstract: This disclosure relates to a chimeric respiratory syncytial vims encoding a chimeric RSV and hMPV F protein and uses of the chimeric virus or components therein in a vaccine. In certain embodiments, this disclosure relates to a live attenuated vaccine comprising an RSV backbone substituting the F proteins of RSV, for a chimeric RSV and hMPV F protein.Type: ApplicationFiled: February 11, 2020Publication date: April 28, 2022Inventors: Martin L. MOORE, Sean TODO, Christopher C. STOBART
-
Patent number: 11235050Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.Type: GrantFiled: October 27, 2016Date of Patent: February 1, 2022Assignee: EMORY UNIVERSITYInventors: Martin L. Moore, Christina Rostad
-
Patent number: 11160857Abstract: This disclosure relates to multivalent enterovirus vaccine compositions and uses related thereto. In certain embodiments, the disclosure relates to vaccine compositions comprising multivalent, mixtures of enterovirus (for example HRV) serotypes or recombinantly produced variants or recombinantly produced viral capsid proteins. In certain embodiments, the disclosure relates to methods of immunization comprising administering an effective amount of compositions disclosed herein to a subject diagnosed with, exhibiting symptoms of, or at risk of an enterovirus infection.Type: GrantFiled: June 15, 2016Date of Patent: November 2, 2021Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Martin L. Moore, Sujin Lee, Minh Trang Nguyen
-
Publication number: 20210100893Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: ApplicationFiled: September 18, 2020Publication date: April 8, 2021Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
-
Patent number: 10792356Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: GrantFiled: January 31, 2019Date of Patent: October 6, 2020Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher C. Stobart
-
Patent number: 10626378Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.Type: GrantFiled: February 14, 2019Date of Patent: April 21, 2020Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Martin L. Moore, Anne Hotard
-
Publication number: 20190224306Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: ApplicationFiled: January 31, 2019Publication date: July 25, 2019Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher C. Stobart
-
Publication number: 20190169579Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.Type: ApplicationFiled: February 14, 2019Publication date: June 6, 2019Inventors: Martin L. Moore, Anne Hotard
-
Patent number: 10232032Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: GrantFiled: March 14, 2014Date of Patent: March 19, 2019Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher C. Stobart
-
Patent number: 10227569Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.Type: GrantFiled: April 11, 2012Date of Patent: March 12, 2019Assignees: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC.Inventors: Martin L. Moore, Anne Hotard
-
Publication number: 20180333477Abstract: This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.Type: ApplicationFiled: October 27, 2016Publication date: November 22, 2018Applicant: Emory UniversityInventors: Martin L. Moore, Christina Rostad
-
Publication number: 20180169215Abstract: This disclosure relates to multivalent enterovirus vaccine compositions and uses related thereto. In certain embodiments, the disclosure relates to vaccine compositions comprising multivalent, mixtures of enterovirus (for example HRV) serotypes or recombinantly produced variants or recombinantly produced viral capsid proteins. In certain embodiments, the disclosure relates to methods of immunization comprising administering an effective amount of compositions disclosed herein to a subject diagnosed with, exhibiting symptoms of, or at risk of an enterovirus infection.Type: ApplicationFiled: June 15, 2016Publication date: June 21, 2018Inventors: Martin L. Moore, Sujin Lee, Minh Trang Nguyen
-
Publication number: 20160030549Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Inventors: Martin L. MOORE, Jia MENG, Anne HOTARD, Elizabeth LITTAUER, Christopher STOBART
-
Publication number: 20140255441Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.Type: ApplicationFiled: July 31, 2012Publication date: September 11, 2014Applicants: CHILDREN'S HEATLHCARE OF ATLANTA, INC., EMORY UNIVERSITYInventors: Richard W. Compans, Baozhong Wang, Martin L. Moore, Fu Shi Quan
-
Publication number: 20120264217Abstract: In certain embodiments, the disclosure relates to vectors containing bacterial nucleic acid sequences and a paramyxovirus gene. Typically, the expression vector comprises a bacterial artificial chromosome (BAC), and a nucleic acid sequence comprising a respiratory syncytial virus (RSV) gene in operable combination with a regulatory element and optionally a reporter gene.Type: ApplicationFiled: April 11, 2012Publication date: October 18, 2012Applicants: CHILDREN'S HEALTHCARE OF ATLANTA, INC., EMORY UNIVERSITYInventors: Martin L. Moore, Anne Hotard